Oncology

With an expansion that includes immunotherapy combination treatments, the American Society of Clinical Oncology (ASCO)’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has now grown to 500 participants and 16 therapies.

High chemotherapy costs are only one reason for the rising cost of cancer care. End-of-life care and hospitalizations are within an oncologist's control and must be better managed given new reimbursement structures.

Authors of the study found that the mean total, chemotherapy, and physician costs were all lower in community settings compared with hospital-based settings for patients with breast, lung, and colorectal cancer. There were also fewer emergency department visits both 3 and 10 days following treatment.

FDA on Thursday authorized a faster approval path for a next-generation sequencing assay developed at Memorial Sloan Kettering Cancer Center (MSK) that represents both a scientific and regulatory breakthrough at the agency.

A mathematical model may help providers better understand which patients will benefit from certain immunotherapy.

Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.

According to a new analysis by Stacy Dusetzina, PhD, and colleagues, state oral parity laws—devised to equate out-of-pocket (OOP) spending for patients, irrespective of whether their treatment is an oral agent or an infusion—are not consistent with reducing patient OOP costs for oral anticancer agents.

We determine a specialist physician phenotype responsive to financial incentives that may be leveraged to identify physicians and markets well-suited for participation in alternative payment models.

A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).

Leading healthcare innovation officer to share information about digital health, managed services, and provider sectors in the healthcare arena.

Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.

According to evidence gathered by the American Society of Clinical Oncology (ASCO), alcohol consumption is linked with an increased risk of cancer and can negatively impact cancer treatment.

Rising rates of diabetes and obesity have been cited in the fact that pancreatic cancer is expected to be the second-leading cause of cancer death by 2020.

With the ACA putting emphasis on preventive care, there has been an immediate increase in breast and coloreactal cancer screenings. A recent study found that incidence rates of early-stage breast and colorectal cancer increased in 2014, but did not vary for late-stage breast and colorectal cancer.

Recent advancements in technology, specifically in detection methods, have demonstrated significant improvement in how early patients are diagnosed with breast cancer and treated.

In a pair of interviews, experts discuss neutropenia resulting from treatment of metastatic breast cancer with CDK4/6 inhibitors.

Increased fiber, especially from cereal, intake after the diagnosis of non-metastatic colorectal cancer (CRC) is associated with lower CRC-specific and overall mortality.

Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.

The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.

As cancer care becomes more expensive and complex, the role of the pharmacist is expanding, from managing the shift to greater use of oral therapies to navigating the revenue cycle, as explored in the new issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care.®

Strong chemotherapy may be part of the treatment plan for patients diagnosed with cancer, but it also comes with risks. A new campaign will empower patients with cancer to better understand and navigate risks such as febrile neutropenia that are associated with strong chemotherapy.

Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.

An overview of factors that make the Oncology Care Model performance period data challenging to navigate and use.